https://www.selleckchem.com/products/AZD0530.html
CKD and type 2 diabetes mellitus interact to increase the risk of major adverse cardiovascular events ( , cardiovascular death, nonfatal myocardial infarction, or stroke) and congestive heart failure. A maladaptive epigenetic response may be a cardiovascular risk driver and amenable to modification with apabetalone, a selective modulator of the bromodomain and extraterminal domain transcription system. We examined this question in a prespecified analysis of BETonMACE, a phase 3 trial. BETonMACE was an event-driven, randomized, double-bl
처럼
논평
공유하다
